We previously showed that UCART19, an allogeneic genome-edited anti-CD19 CAR-T cell therapy, could be safely administered and achieved antileukemic activity in pediatric and adult patients with R/R B-ALL enrolled in two multicenter phase I studies (14, 15). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.